SyStemix reaches the clinic

SyStemix reaches the clinic

For years, companies developing rival technologies for stem cell separation and concentration have made competing claims about the relative virtues of their devices. Until now, only CellPro Inc. has been in a position to provide clinical data on its process. But the initiation of clinical trials of hematopoietic stem cells isolated using SyStemix Inc.'s high speed cell sorter should begin to provide data that will allow observers to assess the clinical relevance of differences between the two companies' systems.

STMX's transplants are 90 percent pure hematopoietic stem cells composed of

Read the full 932 word article

How to gain access

Continue reading with a
two-week free trial.